KRAS and colorectal cancer: Basal total EGFR expression was reduced relative to WT A375 cells in the NRAS Q61K line, and significantly elevated relative to WT in the KRAS G13D line in all conditions, a result that is consistent with reports of resistance to anti-EGFR therapy in colorectal cancer patients with confirmed KRAS G13D mutation [20].